Lipum has recruited all rheumatoid arthritis patients for the final stage of its phase I study with SOL-116. With a 90-day follow-up period remaining, the study is on track for completion around the end of the year. CEO Ola Sandborgh discusses this milestone in an interview.
Read the full article at biostock.se:
https://www.biostock.se/en/2024/09/lipum-approaches-the-finish-line-in-the-study-last-patient-recruited/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se
